Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07370064 | Jan 2026 → Jan 2028 expected | acute myeloid leukemia | Xuzhou Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07370064 ↗ |
| Action | Deplete | “target and destroy cancerous leukemia cells” NCT07370064 ↗ |
| Modality | Cell therapy | “a novel CAR-T cell therapy” NCT07370064 ↗ |
| Target | CD33 | “The therapy is designed to specifically target AML cells by utilizing unique markers (CLL1, CD33, and NKG2D) on the surface of the leukemia cells.” NCT07370064 ↗ |